Melperone

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Template:Short description Template:Short description <templatestyles src="Infobox drug/styles.css"/> Script error: No such module "Infobox".Template:Template otherScript error: No such module "TemplatePar".{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type= | _number_of_combo_chemicals=Script error: No such module "ParameterCount". | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=1622111Fc1ccc(cc1)C(=O)CCCN2CCC(CC2)C1S/C16H22FNO/c1-13-8-11-18(12-9-13)10-2-3-16(19)14-4-6-15(17)7-5-14/h4-7,13H,2-3,8-12H2,1H3DKMFBWQBDIGMHM-UHFFFAOYSA-NTemplate:StdinchiciteTemplate:Stdinchicite | _combo_data= | _physiological_data= | _clinical_data=Template:Drugs.com Oral, intramuscular injectionBuronilN05 | _legal_data=Rx-only

| _other_data=1-(4-fluorophenyl)-4-(4-methylpiperidin-1-yl)butan-1-one

| _image_0_or_2 = Melperone.svgMelperone 3D ball.png | _image_LR =

| _datapage = Melperone (data page) | _vaccine_target=_type_not_vaccine | _legal_all=Rx-only | _ATC_prefix_supplemental=N05 | _has_EMA_link = | CAS_number=3575-80-2 | PubChem=15387 | ChemSpiderID=14646 | ChEBI= | ChEMBL=1531134 | DrugBank=DB09224 | KEGG=D07309 | _hasInChI_or_Key=yes | UNII=J8WA3K39B7 | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =

| _countSecondIDs=Script error: No such module "ParameterCount". | _countIndexlabels=Script error: No such module "ParameterCount". | _trackListSortletter= |QID = |QID2 = |Verifiedfields= |Watchedfields= |verifiedrevid=447616990}}

Melperone (Bunil (PT), Buronil (AT, BE, CZ, DK, FI, NL, NO, SE), Eunerpan (DE))[1] is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. It first entered clinical use in 1960s.[2]

Marketing and indications

It has been tried in treatment-resistant cases of schizophrenia with some (albeit limited) success.[2][3][4][5] It has also been reported effective in the treatment of L-DOPA and other forms of psychosis in Parkinson's disease[6] (although a multicentre, double-blind, placebo-controlled study conducted in 2012 failed to support these findings[7]). It is also known to possess anxiolytic properties.[8] It is marketed in the following countries:[1][9]

<templatestyles src="Div col/styles.css"/>

Script error: No such module "Check for unknown parameters".

Adverse effects

Melperone is reported to produce significantly less weight gain than clozapine and approximately as much weight gain as typical antipsychotics.[10] It is also purported to produce around as much prolactin secretion as clozapine (which is virtually nil).[11] It is also purported to produce sedative effects[12] and QT interval prolongation.[13] It is also known to produce less extrapyramidal side effects than the first-generation (typical) antipsychotic, thiothixene.[14] It can also produce (usually relatively mild) dry mouth.[15]

Other common adverse effects include[16][17][18]

<templatestyles src="Div col/styles.css"/>

Script error: No such module "Check for unknown parameters".
Rare adverse effects include[16][17][18]
Unknown frequency adverse effects include[16][17][18]

<templatestyles src="Div col/styles.css"/>

Script error: No such module "Check for unknown parameters".
  • Seizures (probably rare/uncommon)
  • Increased intraocular pressure
  • Intrahepatic cholestasis (probably rare)
  • Orthostatic hypotension (probably common)
  • Arrhythmias
  • Rash
  • Hyperprolactinemia (which can lead to e.g. galactorrhea, gynecomastia)
  • Weight gain
  • Increased appetite

Interactions

Melperone is reported to be a CYP2D6 inhibitor.[19][20][21]

Pharmacology

Melperone binds to the dopamine D2 receptor, just like all other clinically utilized antipsychotics, but it does so with a very low affinity and hence may be liable to rapidly dissociate from the D2 receptor hence potentially giving it the profile of an atypical antipsychotic.[22]

Receptor Ki [nM][23]
5-HT1A 2,200
5-HT1D 3,400
5-HT2A 230
5-HT2C 2,100
5-HT6 1,254
5-HT7 578
α1 180
α2 150
M1 >10,000
M2 2,400
M3 >10,000
M4 4,400
M5 >10,000
D2 194
D3 347
D4 555
H1 580

Synthesis

File:Melperone synthesis.svg
Thieme Patents:[24][25] 86%:[26]

For the last step of the synthesis the sidechain 4-Chloro-4'-Fluorobutyrophenone [3874-54-2] (1) is attached to 4-Methylpiperidine (4-Pipecoline) [626-58-4] (2).

See also

References

<templatestyles src="Reflist/styles.css" />

  1. a b Script error: No such module "citation/CS1".
  2. a b Script error: No such module "Citation/CS1".
  3. Script error: No such module "Citation/CS1".
  4. Script error: No such module "Citation/CS1".
  5. Script error: No such module "Citation/CS1".
  6. Barbato L, Monge A, Stocchi F, Nordera G. Melperone in the treatment of iatrogenic psychosis in Parkinson’s disease. Funct Neurol. 1996 Aug;11(4):201–7.
  7. Script error: No such module "Citation/CS1".
  8. Script error: No such module "Citation/CS1".
  9. Script error: No such module "citation/CS1".
  10. Script error: No such module "Citation/CS1".
  11. Script error: No such module "Citation/CS1".
  12. Script error: No such module "Citation/CS1".
  13. Script error: No such module "Citation/CS1".
  14. Script error: No such module "Citation/CS1".
  15. Script error: No such module "Citation/CS1".
  16. a b c Template:Cite report
  17. a b c Script error: No such module "Citation/CS1".
  18. a b c Script error: No such module "Citation/CS1".
  19. Script error: No such module "Citation/CS1".
  20. Script error: No such module "Citation/CS1".
  21. Script error: No such module "Citation/CS1".
  22. Script error: No such module "Citation/CS1".
  23. Script error: No such module "citation/CS1".
  24. J Lassen, S Hernestam, N Sterner, U.S. patent 3816433 (1974 to Ferrosan Ab).
  25. BE651144 idem Erik Harry Hernestam Sven, et al.<templatestyles src="Citation/styles.css"/>Template:Citation/make link Script error: No such module "Check for unknown parameters". (1966 to Ferrosan); CA, 63, 13244c
  26. Leyva-Pérez, Antonio; Cabrero-Antonino, Jose R.; Rubio-Marqués, Paula; Al-Resayes, Saud I.; Corma, Avelino (2014). "Synthesis of the ortho/meta/para Isomers of Relevant Pharmaceutical Compounds by Coupling a Sonogashira Reaction with a Regioselective Hydration". ACS Catalysis. 4 (3): 722–731. doi:10.1021/cs401075z.

Script error: No such module "Check for unknown parameters".

External links

Script error: No such module "Navbox".

Script error: No such module "navboxes". Template:Acetylcholine receptor modulators Template:Adrenergic receptor modulators Template:Dopamine receptor modulators Template:Histamine receptor modulators Template:Serotonin receptor modulatorsScript error: No such module "navboxes".Script error: No such module "Check for unknown parameters".